Article Text

Download PDFPDF
Maximal Cytoreduction in Patients With FIGO Stage IIIC to Stage IV Ovarian, Fallopian, and Peritoneal Cancer in Day-to-Day Practice: A Retrospective French Multicentric Study
  1. Mathieu Luyckx, MD*,,
  2. Eric Leblanc, MD, PhD,
  3. Thomas Filleron, PhD*,
  4. Philippe Morice, MD, PhD§,
  5. Emile Darai, MD, PhD,
  6. Jean-Marc Classe, MD, PhD,
  7. Gwenaël Ferron, MD*,
  8. Eberhard Stoeckle, MD, PhD#,
  9. Christophe Pomel, MD, PhD**,
  10. Bénédicte Vinet, MD*,
  11. Elisabeth Chereau, MD,
  12. Cécile Bergzoll, MD** and
  13. Denis Querleu, MD, PhD*,,
  1. *Institut Claudius Regaud, Toulouse France;
  2. Service de Gynécologie — Cliniques Universitaires Saint Luc — Institut de Recherche Experimentale et Clinique, Université Catholique de Louvain, Bruxelles, Belgium;
  3. Centre Oscar Lambret, Lille France;
  4. §Institut Gustave Roussy, Paris, France;
  5. Hôpital Tenon, Paris, France;
  6. Centre René Gaducheau, Nantes, France;
  7. #Institut Bergonnié, Bordeaux, France;
  8. **Centre Jean Perrin, Clermont-Ferrand, France; and
  9. ††Mc Gill University, Montreal, Canada.
  1. Address correspondence and reprint requests to Mathieu Luyckx, MD, Service de Gynécologie, Cliniques Universitaires St. LUC (UCL), avenue Hippocrate 10, 1200 Bruxelles, Belgium. E-mail: mathieu.luyckx{at}


Objectives To evaluate the outcome of maximal cytoreductive surgery in patients with stage IIIC to stage IV ovarian, tubal, and peritoneal cancer regarding overall survival (OS) and disease-free survival (DFS).

Materials and Methods Five hundred twenty-seven patients with stage IIIC (peritoneal) and stage IV (pleural) ovarian, fallopian tube, and peritoneal carcinoma underwent surgery between January 2003 and December 2007 in 7 gynecologic oncology centers in France. Patients undergoing primary and interval debulking surgery were included, whichever the number of chemotherapy cycles. The extent of disease, type of surgical procedure, and amount of residual disease were recorded. A multivariate analysis of the outcome was performed, taking into account the stage, grade, and timing of surgery.

Results Median DFS was 17.9 months, but median OS was not reached at the time of analysis. Complete cytoreductive surgery, without evident residual tumor at the end of the procedure, was obtained in 71% of all patients (primary surgery, 33%). After neoadjuvant therapy, the rate of complete debulking surgery was higher (74%) compared to primary cytoreductive surgery (65%). Twenty-three percent of patients needed “ultra radical surgery” to achieve this goal. The most significant predictive factor for DFS and OS was complete cytoreductive surgery compared to any amount, even minimal (1–10 mm), of residual disease. In the group of patients with complete cytoreductive surgery, the patients undergoing surgery before chemotherapy showed better DFS than those having first chemotherapy.

Conclusion The findings confirm that complete cytoreduction is the criterion standard of surgery in the management of advanced ovarian, peritoneal, and fallopian tube cancer, whatever the timing of surgery. With experienced teams, surgery was completed, without evident residual tumor in 71% of the cases.

  • Cytoreductive surgery
  • Neoadjuvant chemotherapy
  • Ovarian cancer
  • Prognostic factor
  • Residual disease

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.